Analyzing MannKind (NASDAQ:MNKD) and Immuron (NASDAQ:IMRN)

Immuron (NASDAQ:IMRN) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Immuron and MannKind’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
MannKind	-11.08%	-11.21%	-6.31%

Insider and Institutional Ownership

0.1% of Immuron shares are owned by institutional investors. Comparatively, 49.5% of MannKind shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Immuron and MannKind, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1	0	0	0	1.00
MannKind	1	2	7	0	2.60

MannKind has a consensus target price of $9.22, suggesting a potential upside of 139.45%. Given MannKind’s stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Immuron.

Valuation and Earnings

This table compares Immuron and MannKind”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72 million	1.88	-$3.38 million	N/A	N/A
MannKind	$348.97 million	3.55	$5.86 million	($0.13)	-29.62

MannKind has higher revenue and earnings than Immuron.

Volatility & Risk

Immuron has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Summary

MannKind beats Immuron on 7 of the 12 factors compared between the two stocks.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.